Procalcitonin as a marker of pathological conditions of the body during infectious complications (literature review)
https://doi.org/10.18705/2311-4495-2024-11-3-248-252
Abstract
One of the problems of practical healthcare is infectious complications and, as the most serious threat to human health around the globe, antibiotic resistance. Despite the modern arsenal of diagnostic and treatment methods, mortality from infectious complications remains high. In this regard, an active search is currently underway for reliable biological markers for the timely diagnosis of infectious complications. Of particular interest is the current status and recent advances in diagnostics using procalcitonin, both for differentiating the pathogenesis of infectious and non-infectious processes, as well as for optimizing the use of antibiotics.
The review presents current data on procalcitonin as a specific biomarker of bacterial infection. Various possible uses of procalcitonin in clinical practice are shown.
About the Authors
N. S. Alekseeva
Rostov State Medical University
Russian Federation
Competing Interests:
Russian Federation
Alekseeva Natalya Sergeevna, Ph.D. med. Sciences, Associate Professor of the Department of Normal Physiology
Nakhichevansky Lane, 29, Rostov-on-Don, 344022
Competing Interests:
The authors declare no conflict of interest.
V. V. Alekseev
Rostov State Medical University
Russian Federation
Competing Interests:
Russian Federation
Alekseev Vladimir Vyacheslavovich, Dr. med. Sciences, Head. Department of Histology, Cytology and Embryology
Rostov-on-Don
Competing Interests:
The authors declare no conflict of interest.
O. Yu. Kutsevalova
National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Kutsevalova Olga Yurievna, Ph.D. biol. Sciences
Rostov-on-Don
Competing Interests:
The authors declare no conflict of interest.
References
1. Kutsevalova OYu, Pokudina IO, Rozenko DA, et al. Modern problems of antibiotic resistance of gram-negative pathogens of nosocomial infections in the Rostov region. Medical Bulletin of the South of Russia. 2019;10(3):91–96. In Russian DOI: 10.21886/2219-8075-2019-10-3-91-96.
2. Pierrakos C, Velissaris D, Bisdorff M, et al. Biomarkers of sepsis: time for a reappraisal. Crit Care. 2020 Jun 5;24(1):287. DOI: 10.1186/s13054-020-02993-5.
3. Guskova NK, Morozova AA, Rozenko DA, et al. Presepsin as a marker of sepsis in cancer patients after surgical interventions. South Russian Journal of Oncology. 2022;3(2):6–13. In Russian DOI:10.37748/2686-9039-2022-3-2-1.
4. Kaal A, Snel L, Dane M, et al. Diagnostic yield of bacteriological tests and predictors of severe outcome in adult patients with COVID-19 presenting to the emergency department. Emerg Med J. 2021;38(9): 685–691. DOI: 10.1136/emermed-2020-211027.
5. Kutsevalova OYu, Lysenko IB, Kozel YuYu, et al. An integrated approach to the diagnosis of bacterial and fungal bloodstream infections in oncology patients. South Russian Journal of Oncology. 2020;1(4):15–21. In Russian DOI:10.37748/2687-0533-2020-1-4-2.
6. Mobed A, Darvishi M, Tahavvori A, et al. Nanobiosensors for procalcitonin (PCT) analysis. J Clin Lab Anal. 2024;38(3): e25006. DOI: 10.1002/jcla.25006.
7. Van Engelen TSR, Wiersinga WJ, Scicluna BP, et al. Biomarkers in Sepsis. Crit Care Clin. 2018; 34(1):139– 152. DOI: 10.1016/j.ccc.2017.08.010.
8. Lu CY, Kao CL, Hung KC, et al. Diagnostic efficacy of serum presepsin for postoperative infectious complications: a meta-analysis. Front Immunol. 2023;12; 14:1320683. DOI: 10.3389/fimmu.2023.1320683.
9. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–1247. DOI: 10.1007/s00134-021-06506-y.
10. Wang Q, Liu H, Zou L, et al. Early predictors of bacterial pneumonia infection in children with congenital heart disease after cardiopulmonary bypass: a single-centre retrospective study. BMJ Open. 2024;14(3): e076483. DOI: 10.1136/bmjopen-2023-076483.
11. Tatsuoka T, Okuyama T, Takeshita E, et al. Early detection of infectious complications using C-reactive protein and the procalcitonin levels after laparoscopic colorectal resection: aprospective cohort study. Surg Today. 2021;51(3):397–403. DOI:10.1007/s00595-020-02111-6.
12. Vasavada B, Patel H. Postoperative serum procalcitonin versus C-reactive protein as a marker of postoperative infectious complications in pancreatic surgery: a meta-analysis. ANZ J Surg. 2021;91(5):E260– E270. DOI: 10.1111/ans.16639.
13. Rashwan NI, Hassan MH, Mohey El-Deen ZM, et al. Validity of biomarkers in screening for neonatal sepsis - A single center -hospital based study. Pediatr Neonatol. 2019;60(2):149–155. DOI: 10.1016/j.pedneo.2018.05.001.
14. Saura O, Luyt CE. Procalcitonin as a biomarker to guide treatments for patients with lower respiratory tract infections. Expert Review of Respiratory Medicine. 2023;17(8):651–661. DOI:10.1080/17476348.2023.2251394.
15. Lu Y, Song L. Clinical Significance of Procalcitonin, Lactic Acid, and Endotoxin Testing for Children With Severe Pneumonia and Sepsis. Altern Ther Health Med. 2023;29(3):218–223.
16. Kouritas V, Zissis C, Bellenis I. Procalcitonin Measurement in Pleural Fluid to Predict Infectious Complications of the Chest Post Lung Resection. J Invest Surg. 2021;34(12):1317–1321. DOI: 10.1080/08941939.2020.1801912.
17. Florin TA, Ambroggio L, Brokamp C, et al. Biomarkers and Disease Severity in Children With Community-Acquired Pneumonia. Pediatrics. 2020;145(6):e20193728. DOI:10.1542/peds.2019-3728.
18. Roth L, Eshmuminov D, Russo L, et al. Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC. World J Surg Oncol. 2023;12;21(1):5. DOI: 10.1186/s12957-022-02884-9.
19. Dockree S, Brook J, James T, et al. A pregnancy-specific reference interval for procalcitonin. Clin Chim Acta. 2021;513:13–16. DOI: 10.1016/j.cca.2020.12.007.
20. Beaumont R, Tang K, Gwee A. The Sensitivity and Specificity of Procalcitonin in Diagnosing Bacterial Sepsis in Neonates. Hosp Pediatr. 2024;14(3):199–208. DOI: 10.1542/hpeds.2023-007318.
21. Dolci A, Robbiano C, Aloisio E, et al. Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients. Clin Chem Lab Med. 2020;59(2):433–440. DOI: 10.1515/cclm-2020-1361.
22. Heer RS, Mandal AK, Kho J, et al. Elevated procalcitonin concentrations in severe COVID-19 may not reflect bacterial co-infection. Annals of Clinical Biochemistry. 2021;58(5):520–527. DOI: 10.1177/00045632211022380.
23. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. 2023;61(4):2200735. DOI: 10.1183/13993003.00735-2022.
24. Sepsis (in adults). Clinical recommendations. 2022. (In Russ.) https://www.antibiotic.ru/ files/306/kr-sepsis-vzroslye.pdf
25. Farias JS, Villarreal EG, Dhargalkar J, et al. C-reactive protein and procalcitonin after congenital heart surgery utilizing cardiopulmonary bypass: When should we be worried? J Card Surg. 2021;36(11):4301–4307. DOI: 10.1111/jocs.15952.
26. Schuetz P. How to best use procalcitonin to diagnose infections and manage antibiotic treatment. Clin Chem Lab Med. 2022;61(5):822–828. DOI: 10.1515/cclm-2022-1072.
27. Ivaska L, Herberg J, Sadarangani M. Distinguishing community-acquired bacterial and viral meningitis: Microbes and biomarkers. J Infect. 2024;88(3):106111. DOI: 10.1016/j.jinf.2024.01.010.
Review
For citations:
Alekseeva N.S., Alekseev V.V., Kutsevalova O.Yu. Procalcitonin as a marker of pathological conditions of the body during infectious complications (literature review). Translational Medicine. 2024;11(3):248-252. (In Russ.) https://doi.org/10.18705/2311-4495-2024-11-3-248-252
Views:
280
Email this article 